Purpose: Guiding response to neoadjuvant chemotherapy (guided-NACT) allows for an adaptative treatment approach likely to improve breast cancer survival. In this study, our primary aim is to explore the expected cost-effectiveness of guided-NACT using as a case study the first randomized controlled trial that demonstrated effectiveness (GeparTrio trial).
Materials And Methods: As effectiveness was shown in hormone-receptor positive (HR+) early breast cancers (EBC), our decision model compared the health-economic outcomes of treating a cohort of such women with guided-NACT to conventional-NACT using clinical input data from the GeparTrio trial. The expected cost-effectiveness and the uncertainty around this estimate were estimated via probabilistic cost-effectiveness analysis (CEA), from a Dutch societal perspective over a 5-year time-horizon.
Results: Our exploratory CEA predicted that guided-NACT as proposed by the GeparTrio, costs additional €110, but results in 0.014 QALYs gained per patient. This scenario of guided-NACT was considered cost-effective at any willingness to pay per additional QALY. At the prevailing Dutch willingness to pay threshold (€80.000/QALY) cost-effectiveness was expected with 78% certainty.
Conclusion: This exploratory CEA indicated that guided-NACT (as proposed by the GeparTrio trial) is likely cost-effective in treating HR+ EBC women. While prospective validation of the GeparTrio findings is advisable from a clinical perspective, early CEAs can be used to prioritize further research from a broader health economic perspective, by identifying which parameters contribute most to current decision uncertainty. Furthermore, their use can be extended to explore the expected cost-effectiveness of alternative guided-NACT scenarios that combine the use of promising imaging techniques together with personalized treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849576 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154386 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Quality-adjusted Life Years and Costs of Mechanical Thrombectomy for Very Elderly Patients with Acute Ischaemic Stroke.
Neurol Med Chir (Tokyo)
December 2024
Department of Clinical Epidemiology, Hyogo Medical University.
Article Synopsis
- This study investigates the cost-effectiveness of using mechanical thrombectomy (MT) alongside standard medical care (SMC) for patients aged 90 and older suffering from acute ischemic stroke (AIS).
- A simulation model estimated that MT with SMC provided 1.463 quality-adjusted life years (QALYs) at a cost of 14,553,772 Yen, compared to 1.054 QALYs for SMC alone, which cost 13,732,646 Yen.
- The findings suggest that the incremental cost-effectiveness ratio (ICER) of MT with SMC is 2,009,744 Yen per QALY, indicating a 66% chance that this approach
Microsimulation Estimates of Decision Uncertainty and Value of Information Are Biased but Consistent.
Med Decis Making
December 2024
Department of Health Policy, Stanford School of Medicine, Stanford, CA, USA.
Purpose: Individual-level state-transition microsimulations (iSTMs) have proliferated for economic evaluations in place of cohort state transition models (cSTMs). Probabilistic economic evaluations quantify decision uncertainty and value of information (VOI). Previous studies show that iSTMs provide unbiased estimates of expected incremental net monetary benefits (EINMB), but statistical properties of iSTM-produced estimates of decision uncertainty and VOI remain uncharacterized.
View Article and Find Full Text PDFMultiple Sclerosis Fatigue Self-Management: Strategies and Influencing Factors 5 Years After a Multimodal Intervention.
Int J MS Care
October 2024
From the Research Department, Veterans Affairs Portland Health Care System, Portland, OR.
Background: Fatigue: Take Control (FTC) is a multimodal self-management program. Results of a previous clinical trial showed its effectiveness at improving fatigue related to multiple sclerosis (MS). The objectives of this study were to use the very long-term data from the FTC study to understand fatigue management strategies used 5 years after enrollment, identify facilitators and barriers to utilizing strategies, and explore the potential relationships between the strategy used and fatigue outcomes.
View Article and Find Full Text PDFEffectiveness of Protection Motivation Theory on clinical factors, behavior change, and cardiovascular disease: An integrative review.
Int J Nurs Stud Adv
December 2024
Federation University of Australia, Victoria, Australia.
Objective: To identify and synthesize the primary evidence on the effectiveness of Protection Motivation Theory on and cardiovascular disease and diseases that are risk factors for cardiovascular disease.
Method: An integrative review was conducted using the Whittemore and Knafl method (2005).
Results: Eleven articles met the inclusion and quality assessment criteria.
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Diabetes Ther
December 2024
Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
Introduction: This analysis aimed to evaluate the long-term cost-effectiveness of tirzepatide 5 mg versus dulaglutide 0.75 mg (both administered once weekly) in people not achieving glycemic control on metformin, based on the results of the head-to-head SURPASS J-mono trial from a Japanese healthcare payer perspective.
Methods: A cost-utility analysis was performed over a 50-year time horizon using an implementation of the UKPDS Outcomes Model 2 developed in Microsoft Excel.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!